Drug resistance in leishmaniasis

Clinical Microbiology Reviews

Volumn 19, Issue 1, 2006, Pages 111-126

  Croft, Simon L ^a,d   Sundar, Shyam ^b   Fairlamb, Alan H ^c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b BANARAS HINDU UNIVERSITY   (India)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d Drugs for Neglected Diseases Initiative DNDi   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ALLOPURINOL RIBOSIDE; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; ANTIMONY DERIVATIVE; FLUCONAZOLE; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; IMIQUIMOD; ITRACONAZOLE; KETOCONAZOLE; MEGLUMINE ANTIMONATE; MILTEFOSINE; NEW DRUG; NUCLEOSIDE ANALOG; ORNITHINE DECARBOXYLASE; PAROMOMYCIN; PENTAMIDINE; PYRROLE DERIVATIVE; SITAMAQUINE; STIBOGLUCONATE SODIUM;

AMASTIGOTE; CELL PH; CLINICAL TRIAL; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; ENDEMIC DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INDIA; LEISHMANIA; LEISHMANIA BRAZILIENSIS; LEISHMANIA CHAGASI; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; LEISHMANIA TARENTOLAE; LEISHMANIA TROPICA; REVIEW; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; DRUG RESISTANCE; HUMANS; LEISHMANIA; LEISHMANIASIS; PARASITIC SENSITIVITY TESTS;

HUMAN IMMUNODEFICIENCY VIRUS; LEISHMANIA BRAZILIENSIS; LEISHMANIA DONOVANI; LEISHMANIA DONOVANI CHAGASI; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; LEISHMANIA TARENTOLAE; LEISHMANIA TROPICA; PROTOZOA;

EID: 31544439919     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/CMR.19.1.111-126.2006     Document Type: Review

References (167)

1. Abdo, M. G., W. M. Elamin, K. A. Khalil, and M. M. Mukhtar. 2003. Antimony-resistant Leishmania donovani in eastern Sudan: incidence and in vitro correlation. East. Mediterr. Health J. 9:837-843.
2. Aikat, B. K., S. Sahaya, A. G. Pathania, P. K. Bhattacharya, N. Desai, L. S. Prasad, S. Mishra, and S. Jain. 1979. Clinical profile of cases of kala-azar in Binar. Indian J. Med. Res. 70:563-570.
3. Al-Jaser, M. H. 1995. Drug sensitivity of cutaneous leishmaniasis in Al-Kharj, Saudi Arabia. Ph.D. thesis. University of London, London, England.
4. Al-Jaser, M., A. El-Yazigi, and S. L. Croft. 1995. Pharmacokinetics of antimony in patients treated with sodium stibogluconate for cutaneous leishmaniasis. Pharm. Res. 12:113-116.
5. Allen, S., and R. A. Neal. 1989. The in vitro susceptibility of macrophages infected with amastigotes of Leishmania spp. to pentavalent antimonial drugs and other compounds with special relevance to cutaneous isolates, p. 711-720. In D. T. Hart (ed.). Leishmaniasis. Plenum Press, New York, N.Y.
6. Arevalo, I., B. Ward, R. Miller, T. C. Meng, E. Najar, E. Alvarez, G. Matlashenski, and A. Llanos-Cuentas. 2001. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin. Infect. Dis. 33:1847-1851.
7. Ariyanayagam, M. R., and A. H. Fairlamb. 2001. Ovothiol and trypanothione as antioxidants in trypanosomatids. Mol. Biochem. Parasitol. 115: 189-198.
8. Asilian, A., T. Jalayer, M. Nilforooshzadeh, K. E. Ghassemi, R. Peto, S. Wayling, P. Olliaro, and E. Modabber. 2003. Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran. Bull. W. H. O. 81:353-359.
9. Avila, J. L., and M. A. Casanova. 1982. Comparative effects of 4-aminopyrazolopyrimidine, its 2′-deoxyriboside derivative, and allopurinol on in vitro growth of American Leishmania species. Antimicrob. Agents Chemother. 22:380-385.
10. Basselin, M., H. Denise, G. H. Coombs, and M. P. Barrett. 2002. Resistance to pentamidine in Leishmania mexicana involves exclusion of the drug from the mitochondrion. Antimicrob. Agents Chemother. 46:3731-3738.
11. Beach, D. H., L. J. Goad, and G. G. Holz, Jr. 1988. Effects of antimycotic azoles on growth and sterol biosynthesis of Leishmania promastigotes. Mol. Biochem. Parasitol. 31:149-162.
12. Berhe, N., D. Wolday, A. Hailu, Y. Abraham, A. Ali, T. Gebre-Michael, P. Desjeux, A. Sonnerborg, H. Akulfo, and S. Britton. 1999. HIV viral load and response to antileishmanial chemotherapy in co-infected patients. AIDS 13:1921-1925.
13. Berman, J. D. 1981. Activity of imidazoles against Leishmania tropica in human macrophage cultures. Am. J. Trop. Med. Hyg. 30:566-569.
14. Berman, J. D., R. Badaro, C. P. Thakur, K. M. Wasunna, K. Behbehani, R. Davidson, V. Kuzoe, E. Pang, K. Weerasuriya, and A. D. Bryceson. 1998. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull. W. H. O. 76:25-32.
15. Berman, J. D., J. D. Chulay, L. D. Hendricks, and C. N. Oster. 1982. Susceptibility of clinically sensitive and resistant Leishmania to pentavalent antimony in vitro. Am. J. Trop. Med. Hyg. 31:459-465.
16. Berman, J. D., J. V. Gallalee, and J. M. Best. 1987. Sodium stibogluconate (Pentostam) inhibition of glucose catabolism via the glycolytic pathway, and fatty acid beta-oxidation in Leishmania mexicana amastigotes. Biochem. Pharmacol. 36:197-201.
17. Berman, J. D., and L. S. Lee. 1983. Activity of 8-aminoquinolines against Leishmania tropica within human macrophages in vitro. Am. J. Trop. Med. Hyg. 32:753-759.
18. Berman, J. D., D. Waddell, and B. D. Hanson. 1985. Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate. Antimicrob. Agents Chemother. 27:916-920.
19. Bjorkman, J., I. Nagaev, O. G. Berg, D. Hughes, and D. I. Andersson. 2000. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 287:1479-1482.
20. Boelaert, M., S. Rijal, S. Regmi, R. Singh, B. Karki, D. Jacquet, E. Chappuis, L. Campino, P. Desjeux, D. Le Ray, S. Koirala, and P. Van der Stuyft. 2004. A comparative study of the effectiveness of diagnostic tests for visceral leishmaniasis. Am. J. Trop. Med. Hyg. 70:72-77.
21. Bray, P. G., M. P. Barrett, S. A. Ward, and H. P. de Koning. 2003. Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. Trends Parasitol. 19:252-239.
22. Brochu, C., J. Wang, G. Roy, N. Messier, X. Y. Wang, N. G. Saravia, and M. Ouellette. 2003. Antimony uptake systems in the protozoan parasite Leishmania and accumulation differences in antimony-resistant parasites. Antimicrob. Agents Chemother. 47:3073-3079.
23. Bryceson, A. 2001. A policy for leishmaniasis with respect to the prevention and contiol of drug resistance. Trop. Med. Int. Health 6:928-934.
24. Buckner, F. S., A. J. Wilson, T. C. White, and W. C. Van Voorhis. 1998. Induction of resistance to azole drugs in Trypanosoma cruzi. Antimicrob. Agents Chemother. 42:3245-3250.
25. Burguera, J. L., M. Burguera, Y. Petit de Pena, A. Lugo, and N. Anez. 1993. Selective determination of antimony(III) and antimony(V) in serum and urine and of total antimony in skin biopsies of patients with cutaneous leishmaniasis treated with meglumine antimonate. J. Trace Elem. Med. Biol. 10:66-70.
26. Callahan, H. L., and S. M. Beverley. 1991. Heavy metal resistance: a new role for F-glycoproteins in Leishmania. J. Biol. Chem. 266:18427-18430.
27. Callahan, H. L., A. C. Portal, R. Devereaux, and M. Grogl. 1997. An axenic amastigote system for drug screening. Antimicrob. Agents Chemother. 41: 818-822.
28. Callahan, H. L., W. L. Roberts, P. M. Rainey, and S. M. Beverley. 1994. The PGPA gene of Leishmania major mediates antimony (SbIII) resistance by decreasing influx and not by increasing efflux. Mol. Biochem. Parasitol. 68:145-149.
29. Carson, P. E. 1984. 8-aminoquinolines. p. 83-121. In W. Peters and W. H. G. Richards (ed.). Antimalarial drugs 11. Springer-Verlag, Berlin, Germany.
30. Carter, K. C., S. Sundar, C. Spiekett, O. C. Pereira, and A. B. Mullen. 2003. The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis. Antimicrob. Agents Chemother. 47:1529-1535.
31. Chunge, C. N., G. Gachihi, R. Muigai, K. Wasunna, J. R. Rashid, J. D. Chulay, G. Anabwani, C. N. Oster, and A. D. Bryceson. 1985. Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol. Trans. R. Soc. Trop. Med. Hyg. 79:715-718.
32. Chunge, C. N., J. Owate, H. O. Pamba, and L. Donno. 1990. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans. R. Soc. Trop. Med. Hyg. 84:221-225.
33. Coelho, A. C., S. M. Beverley, and P. C. Cotrim. 2003. Functional genetic identification of PRPI, an ABC transporter superfamily member conferring pentamidine resistance in Leishmania major. Mol. Biochem. Parasitol. 130: 83-90.
34. Collin, S., R. Davidson, K. Ritmeijer, K. Kens, Y. Melaku, S. Kipngetich, and C. Davies. 2004. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin. Infect. Dis. 38:612-619.
35. Coombs, G. H., C. R. Wolf, V. M. Morrison, and J. A. Craft. 1990. Changes in hepatic xenobiotic-metabolising enzymes in mouse liver following infection with Leishmania donovani. Mol. Biochem. Parasitol. 41:17-24.
36. Croft, S. L., and R. Brun. 2003. In vitro and in vivo models for the identification and evaluation of drugs active against Trypanosoma and Leishmania, p. 165-175. In A. H. Fairlamb, R. Ridley, and H. Vial (ed.). Drugs against parasitic diseases: R&D methodologies and issues. [Online.] World Health Organization. Geneva, Switzerland. http://www.who.int/tdr/publication /publications/prd-drug.htm.
37. Croft, S. L., and G. H. Coombs. 2003. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 19: 502-508.
38. Croft, S. L., and K. Seifert. 2005. Miltefosine: interactions with other anti-leishmanial drugs. Abstracts of the 3rd World Congress on Leishmaniosis. 10-15 April 2005. Palermo, Italy, p. 57.
39. Croft, S. L., and V. Yardley. 2002. Chemotherapy of leishmaniasis. Curr. Pharm. Des. 8:319-342.
40. Cruz, I., M. A. Morales, I. Noguer, A. Rodriguez, and J. Alvar. 2002. Leishmania in discarded syringes from intravenous drug users. Lancet 359: 1124-1125.
41. Cunningham, M. L., and A. H. Fairlamb. 1995. Trypanothione reductase from Leishmania donovani. Purification, characterisation and inhibition by trivalent antimonials. Eur. J. Biochem. 230:460-468.
42. Cupolillo, E., E. Medina-Acosta, H. Noyes, H. Momen, and G. Grimaldi, Jr. 2000. A revised classification for Leishmania and Endotrypanum. Parasitol. Today 16:142-144.
43. Davies, C. R., P. Kaye, S. L. Croft, and S. Sundar. 2003. Leishmaniasis: new approaches to disease control. BMJ 326:377-382.
44. Davies, J., and G. D. Wright. 1997. Bacterial resistance to aminoglycoside antibiotics. Trends Microbiol. 5:234-240.
45. Davison, H. C., J. C. Low, and M. E. Woolhouse. 2000. What is antibiotic resistance and how can we measure it? Trends Microbiol. 8:554-559.
46. Demon, H., J. C. McGregor, and G. H. Coombs. 2004. Reduction of antileishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase. TDRI. Biochem. J. 381:405-412.
47. Desjeux, P. 2001. The increase in risk factors for leishmaniasis worldwide. Trans. R. Soc. Trop. Med. Hyg. 95:239-243.
48. Desjeux, P., and J. Alvar. 2003. Leishmania/HIV co-infections: epidemiology in Europe. Ann. Trop. Med. Parasitol. 97(Suppl. 1):3-15.
49. Dey, S., K. Papadopoulou, A. Haimeur, G. Roy, K. Grondin, D. Dou, B. P. Rosen, and M. Ouellette. 1994. High level arsenite resistance in Leishmania tarentolac is mediated by an active extrusion system. Mol. Biochem. Parasitol. 67:49-57.
50. Dietze, R., S. F. Carvalho, L. C. Valli, J. Berman, T. Brewer, W. Milhous, J. Sanchez, B. Schuster, and M. Grogl. 2001. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused hy Leishmania chagasi. Am. J. Trop. Med. Hyg. 65:685-689.
51. Di Giorgio, C., F. Faraut-Gambarelli, A. Imbert, P. Minodier, M. Gasquet, and H. Dumon. 1999. Flow cytometric assessment of amphotericin B susceptibility in Leishmania infantum isolates from patients with visceral leishmaniasis. J. Antimicrob. Chemother. 44:71-76.
52. Docampo, R., and S. N. Moreno. 1986. Free radical metabolism of antiparasitic agents. Fed. Proc. 45:2471-2476.
53. Durand, R., M. Paul, F. Pratlong, D. Rivollet, M. L. Dubreuil-Lemaire, R. Houin, A. Astier, and M. Deniau. 1998. Leishmania infantum: lack of parasite resistance to amphotericin B in a clinically resistant visceral leishmaniasis. Antimicrob. Agents Chemother. 42:2141-2143.
54. Ellis, D. 2002. Amphotericin B: spectrum and resistance. J. Antimicrob. Chemother. 49(Suppl. 1):7-10.
55. el-On, J., S. Halevy, M. H. Grunwald, and L. Weinrauch. 1992. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. J. Am. Acad. Dermatol. 27:227-231.
56. el-On, J., and A. D. Hamburger. 1987. Topical treatment of New and Old World cutaneous leishmaniasis in experimental animals. Trans. R. Soc. Trop. Med. Hyg. 81:734-737.
57. Ephros, M., A. Bitnun, P. Snaked, E. Waldman, and D. Zilberstein. 1999. Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes. Antimicrob. Agents Chemother. 43:278-282.
58. Ephros, M., E. Waldman, and D. Zilberstein. 1997. Pentostam induces resistance to antimony and the preservative chlorocresol in Leishmania donovani promastigotes and axenically thrown amastigotes. Antimicrob. Agents Chemother. 41:1064-1068.
59. Ercoli, N. 1966. Drug responsiveness in experimental cutaneous leishmaniasis. Exp. Parasitol. 19:320-326.
60. Escobar, P., S. Matu, C. Marques, and S. L. Croft. 2002. Sensitivities of Leishmania species to hexadecylphosphoeholine (miltefosine). ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Trop. 81:151-157.
61. Escobar, P., V. Yardley, and S. L. Croft. 2001. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob. Agents Chemothcr. 45:1872-1875.
62. Faraut-Gambarelli, F., R. Piarroux, M. Deniau, B. Giusiano, P. Marty, G. Michel, B. Faugere, and H. Dumon. 1997. In vitro and in vivo resistance of Leishmania infantum to meglumine amimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob. Agents Chemother. 41:827-830.
63. Ferreira Cdos, S., P. S. Martins, C. Demicheli, C. Brochu, M. Ouellette, and F. Frezard. 2003. Thiol-induced reduction of antimony(V) into antimony (III): a comparative study with trypanothione, cysteinyl-glycine, cysteine and glulathione. Biometals 16:441-446.
64. Fong, D., M. M. Chan, R. Rodriguez, E. J. Gately, J. D. Berman, and M. Grogl. 1994. Paromomycin resistance in Leishmania tropica: lack of correlation with mutation in the small subunit ribosomal RNA gene. Am. J. Trop. Med. Hyg. 51:758-766.
65. Frezard, F., C. Demicheli, C. S. Ferreira, and M. A. Costa. 2001. Glutathione-induced conversion of pentavulent antimony to trivalent antimony in meglumine amimoniate. Antimicrob. Agents Chemother. 45:913-916.
66. Fries, D. S., and A. H. Fairlamb. 2003. Antiprotozoal agents, p. 1033-1087. In J. Abraham (ed.), Burger's medicinal chemistry and drug discovery: chemotherapeutic agents. John Wiley & Sons, New York, N.Y.
67. Garnier, T., and S. L. Croft. 2002. Topical treatment for cutaneous leishmaniasis. Curr. Opin. Investig. Drugs 3:538-544.
68. Ghannoum, M. A., and L. B. Rice. 1999. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev. 12:501-517.
69. Glaser, T. A., J. E. Baatz, G. P. Kreishman, and A. J. Mukkada. 1988. pH homeostasis in Leishmania donovani amastigotes and promastigotes. Proc. Natl. Acad. Sci. USA 85:7602-7606.
70. Goodwin, L. G., and J. E. Page. 1943. A study of the excretion of organic antimonials using a polarographic procedure. Biochem. J. 37:198-209.
71. Gourbal, B., N. Sonue, H. Bhattacharjee, D. Legare, S. Sundar, M. Ouellette, B. P. Rosen, and R. Mukhopadhyay. 2004. Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J. Biol. Chem. 279: 31010-31017.
72. Goyard, S., H. Segawa, J. Gordon, M. Showalter, R. Duncan, S. J. Tureo, and S. M. Beverley. 2003. An in vitro system for developmental and genetic studies of Leishmania donovani phosphoglycans. Mol. Biochem. Parasitol. 130:31-42.
73. Gradoni. L., M. Gramiceia, and A. Scalone. 2003. Visceral Ieishmaniasis treatment, Italy. Emerg. Infect. Dis. 9:1617-1620.
74. Gramiceia. M., L. Gradoni, and S. Orsini. 1992. Decreased sensitivity Ki mcgluniine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment. Ann. Trop. Med. Parasitol. 86:613-620.
75. Grogl, M., A. M. Oduola, L. D. Cordero, and D. E. Kyle. Leishmania spp.: development of Pentostam-resistant clones in vitro by discontinuous drug exposure. Exp. Parasitol. 69:78-90.
76. Grondin, K., A. Haimeur. R. Mukhopadhyay, B. P. Rosen, and M. Oyellette. 1997. Co-amplification of the gamma-glutamylcysteinc synthetase gene gsh I and of the ABC transporter gene pgpA in arsenite-resistant Leishmania tarentolae. EMBO J. 16:3057-3065.
77. Guerin, P. J., P. Olliaro, S. Sundar, M. Boelaert, S. L. Croft, P. Desjeux, M. K. Wasunna, and A. D. Bryceson. 2002. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect. Dis. ii:494-501.
78. Haimeur, A., C. Guimond, S. Pilote, R. Mukhopadhyay, B. P. Rosen, R. Poulin, and M. Ouellette. 1999. Elevated levels of polyamincs and trypanothione resulting from overexpression of the ornithine decarboxylase gene in arsenite-resistant Leishmania. Mol. Microbiol. 34:726-735.
79. Hayes, J. D., and C. R. Wolf. 1990. Molecular mechanisms of drug resistance. Biochem. J. 272:281-295.
80. Ibrahim, M. E., M. Hag-Ali, A. M. el-Hassan, T. G. Theander, and A. Kharazmi. 1994. Leishmania resistant to sodium stiboglucomite: drug-as-sociated macrophage-dependent killing. Parasitol. Res. 80:569-574.
81. Jha, S. N., N. K. Singh, and T. K. Jha. 1991. Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial. J. Assoc. Physicians India 39:314-316.
82. Jha, T. K. 1983. Evaluation of diamidine compound (pentamidinc isethionate) in the treatment resistant cases of kala-azar occurring in North Bihar, India. Trans. R. Soc. Trop. Med. Hyg. 77:167-170.
83. Jha, T. K., N. K. Singh, and S. N. Jha. 1992. Therapeutic use of sodium stibogluconate in kala-azar from some hyperendemic districts of N. Bihar, India. (Abstract) J. Assoc. Physicians India 40:868.
84. Jha, T. K., S. Sundar, C. P. Thakur, A. J. Sabin, J. Horton, and J. M. Felton. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am. J. Trop. Med. Hyg.. in press.
85. Jiang, X., and X. Wang. 2004. Cytochrome C-mediated apoptosis. Annu. Rev. Biochem. 73:87-106.
86. Kelly, S. L., D. C. Lamb, M. Taylor, A. J. Corran, K. C. Baldwin, and W. G. Powderly. 1994. Resistance to amphoteriein B associated with defective sterol delta 8->7 isomerase in a Cryptoeoccus neoformans strain from an AIDS patient. FEMS Microbiol. Lett. 122:39-42.
87. Kinnamon, K. E., E. A. Steck, P. S. Loizeanx, W. L. Hanson, W. L. Chapman. Jr., and V. B. Waits. 1978. The antileishmanial activity of lepidines. Am. J. Trop. Med. Hyg. 27:751-757.
88. Koutinas, A. F., M. N. Saridomichelakis, M. F. Mylonakis, L. Leontides, Z. Polizopoulou, C. Billinis, D. Argyriadis, N. Diakon, and O. Papadopoulos. 2001. A randomised, blinded, placebo-controlled clinical trial with allopurinol in canine leishmaniosis. Vet. Parasitol. 98:247-261.
89. Laguna, F., R. Lopez-Velez, F. Pulido, A. Salas, J. Torre-Cisneros, E. Torres, F. J. Medrano, J. Sanz, G. Pico, J. Gomez-Rodrigo, J. Pasquau, J. Alvar. et al. 1999. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with aphoteriein B. AIDS 13:1063-1069.
90. Laguna, F., S. Videla, M. E. Jimenez-Mejias, G. Sirera, J. Torre-Cisneros. E. Ribera, D. Prados, B. Clotet, M. Sust, R. Lopez-Velez, and J. Alvar. 2003. Amphotericin B lipid complex versus mcgluminc antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J. Antimicrob. Chemother. 52:464-468.
91. Legare, D., D. Richard, R. Mukhopadhyay, Y. D. Stierhof, B. P. Rosen, A. Haimeur, B. Papadoponlou, and M. Ouelletle. 2001. The Leishmania ATP-binding cassette protein PGPA is an intracellular metal-thiol transporter ATPase. J. Biol. Chem. 276:26301-26307.
92. Levin, B. R., M. Lipsitch, and S. Bonhoeffer. 1999. Population biology, evolution, and infectious disease: convergence and synthesis. Science 283: 806-809.
93. Levin, B. R., V. Perrot, and N. Walker. 2000. Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Genetics 154:985-997.
94. Lewin, S., G. Schonian, N. El Tai, L. Oskam, P. Bastien, and W. Presber, 2002. Strain typing in Leishmania donovani by using sequence-confirmed amplified region analysis. Int. J. Parasitol. 32:1267-1276.
95. Leyden, J. 1998. Pharmacokinetrcs and pharmacology of terbinafine and itraconazole. J. Am. Acad. Dermatol. 38:S42-S47.
96. Lira. R., S. Sundar. A. Makharia, R. Kenney, A. Gam, E. Saraiva, and D. Sacks. 1999. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J. Infect. Dis. 180:564-567.
97. Lo, J. F., H. F. Wang, M. F. Tam, and T. C. Lee. 1992. Glulathione S-transferase pi in an arsenic-resistant Chinese hamster ovary cell line. Biochem. J. 288:977-982.
98. Lopez-Velez. R. 2003. The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV. Ann. Trop. Med. Parasitol. 97(Suppl. 1):143-147.
99. Lugo de Yarbuh, A., N. Anez, Y. Petit de Pena, J. L. Burguera, and M. Burguera. 1994. Antimony determination in tissues and serum of hamsters infected with Leishmania garuhami and treated with meglumine amtimoniate. Ann. Trop. Med. Parasitol. 88:37-41.
100. Maarouf, M., M. T. Adeline. M. Solignae, D. Vautrin, and M. Robert-Gero. 1998. Development and characterization of paromomycin-resistant Leishmania donovani promastigotes. Parasite 5:167-173.
101. Maarouf, M., Y. de Kouchkovsky. S. Brown, P. X. Petit, and M. Robert-Gero. 1997. In vivo interference of paromomycin with mitochondrial activity of Leishmania. Exp. Cell. Res. 232:339-348.
102. Maarouf, M., F. Lawrence, S. L. Croft, and M. Robert-Gero. 1995. Ribosomes of Leishmania are a target for the aminoglycosides. Parasitol. Res. 81:421-425.
103. Marr, J. J. 1991. Purine analogs as chemotherapeutic agents in leishmaniasis and American trypanosomiasis. J. Lab. Clin. Med. 118:111-119.
104. Mbongo, N., P. M. Loiseau, M. A. Billion, and M. Robert-Gero. 1998. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. 42:352-357.
105. Meyerhoff, A. 1999. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin. Infect. Dis. 28:42-51.
106. Molina, R., L. Gradoni, and J. Alvar. 2003. HIV and the transmission of Leishmania. Ann. Trop. Med. Parasitol. 97(Suppl. 1):29-45.
107. Mukhopadhyay, R., S. Dey. N. Xu. D. Gage, J. Lighthody, M. Ouellette, and B. P. Rosen. 1996. Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania. Proc. Natl. Acad. Sci. USA 93:10383-10387.
108. Murray. H. W., J, Hariprashad, and R. E. Fichtl. 1993. Treatment of experimental visceral leishmaniasis in a T-cell-deficient host: response to amphotericin B and pentamidine. Antimicrob. Agents Chemother. 37:1504-1505.
109. Murray. H. W., M. J. Oca. A. M. Granger, and R. D. Schreiber. 1989. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. J. Clin. Investig. 83:1253-1257.
110. Navin, T. R., B. A. Arana, K. E. Arana, J. D. Berman, and J. F. Chajon. 1992. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J. Infect. Dis. 165:528-534.
111. Neal, R. A., S. Allen. N. McCoy, P. Olliaro, and S. L. Croft. 1995. The sensitivity of Leishmania species to aminosidine. J. Antimicrob. Chemother. 35:577-584.
112. Neal, R. A., and S. L. Croft. 1984. An in-vitro system for determining the activity of compounds against the intracellular amastigote form of Leishmania donovani. J. Antimicrob. Chemother. 14:463-475.
113. Nelson, D. J., S. W. LaFon. J. V. Tuttle, W. H. Miller, R. L. Miller, T. A. Krenitsky, G. B. Elion. R. L. Herons, and J. J. Marr. 1979. Allopurinol ribonucteoside as an antileishmanial agent. Biological effects, metabolism, and enzymatic phosphorylation. J. Biol. Chem. 254:11544-11549.
114. Ouellette. M., and P. Borst. 1991. Drug resistance and P-glycoprotein gene amplification in the protozoan parasite Leishmania. Res. Microbiol. 142: 737-746.
115. Ouellette, M., E. Hettema, D. Wust, F. Fase-Fowler, and P. Borst, 1991. Direct and inverted DNA repeats associated with P-glycoprotein gene amplification in drug resistant Leishmania. EMBO J. 10:1009-1016.
116. Papadopoulou, B., G. Roy, S. Dey, B. P. Rosen, M. Olivier, and M. Ouellette, 1996. Gene disruption of the P-glycoprotein related gene pgpa of Leishmania tarentolac. Biochem. Biophys. Res. Commun. 224:772-778.
117. Perez-Victoria, F. J., S. Castanys, and F. Gamarro. 2003. Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug. Antimicrob. Agents Chemother. 47:2397-2403.
118. Perez-Victoria, F. J., F. Gamarro. M. Ouellette, and S. Castanys. 2003. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J. Biol. Chem. 278:49965-49971.
119. Perez-Victoria. J. M., A. Di Pietro. D. Barron, A. G. Ravelo, S. Castanys, and F. Gamarro. 2002. Multidrug resistance phenotype mediated by the P-glycoprotein-like transporter in Leishmania: a search for reversal agents. Curr. Drug Targets 3:311-333.
120. Peters, W. 1981. The treatment of kala-azar - new approaches to an aid problem. Indian J. Med. Res. 73(Suppl.):1-18.
121. Pourshafie, M., S. Morand. A. Virion, M. Rakolomanga, C. Dupuy, and P. M. Loiseau. 2004. Cloning of S-adenosyl-L-methionine:C-24-Δ-sterol- methyltransferase (ERG6) from Leishmania donovani and characterization of mRNAs in wild-type and amphotericin B-resistant promastigotes. Antimicrob. Agents Chemother. 48:2409-2414.
122. Rangel. H., F. Dagger, A. Hernandez. A. Liendo. and J. A. Urbina. 1996. Naturally azole-resistant Leieshmania braziliensis proniastigoles are rendered susceptible in the presence of terbinafine: comparative study with azole-susecptible Leishmania mexicana promastigotes. Antimicrob. Agents Chemother. 40:2785-2791.
123. Rijal, S., M. Boelaert, S. Regmi, B. M. Karki, D. Jacquet, R. Singh, M. L. Chance, F. Chappuis, M. Hommel, P. Desjeux. P. Van der Stnyl't, D. Le Ray, and S. Koirala. 2004. Evaluation of a urinary antigen-based latex agglutination test in thc diagnosis of kala-azar in eastern Nepal. Trop. Med. Int. Health 9:724-729.
124. Rijal, S., F. Chappuis, R. Singh, P. A. Bovier, P. Acharya, B. M. Karki, M. L. Das, P. Desjeux, L. Loutan, and S. Koirala. 2003. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans. R. Soc. Trop. Med. Hyg. 97:350-354.
125. Roberts, C. W., R. McLeod. D. W. Rice. M. Ginger, M. L. Chance, and L. J. Goad. 2003. Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol. Biochem. Parasitol. 126:129-142.
126. Roberts, W. L., and P. M. Rainey. 1993. Antileishmanial activity of sodium stibogluconate fractions. Antimicrob. Agents Chemother. 37:1842-1846.
127. Samanta, T. B., N. Das, M. Das, and R. Marik. 2003. Mechanism of impairment of cytochrome P450-dependent metabolism in hamster liver during leishmaniasis. Biochem. Biophys. Res. Commun. 312:75-79.
128. Seifert, K., S. Matu. F. Javier Perez-Victoria, S. Castanys, F. Gamarro, and S. L. Croft. 2003. Characterisation of leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int. J. Antimicrob. Agents 22:380-387.
129. Sereno. D., M, Cavaleyra. K. Zemzoumi, S. Maquaire, A. Ouaissi, and J. L. Lemesre. 1998. Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action. Antimicrob. Agents Chemother. 42:3097-3102.
130. Sereno. D., P. Holzmuller. I. Mangot, G. Cuny, A. Ouaissi, and J. L. Lemesre. 2001. Antimonial-mediated DNA fragmentation in Leishmania infantum amastigotes. Antimicrob. Agents Chemother. 45:2064-2069.
131. Sereno. D., and J. L. Lemesre. 1997. Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrob. Agents Chemother. 41:972-976.
132. Shaked-Mishan. P., N. Ulrich, M. Ephros, and D. Zilberstein. 2001. Novel Intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani. J. Biol. Chem. 276:3971-3976.
133. Shapiro, T. A., J. B. Were, K. Danso, D. J. Nelson, R. E. Desjardins, and C. L. Pamplin III. 1991. Pharmacokinetics and metabolism of allopurinol riboside. Clin. Pharmacol. Ther. 49:506-514.
134. Singh, A. K., B. Papadopoulou, and M. Ouellette. 2001. Gene amplilication in amphotericin B-resistant Leishmania tarentolae. Exp. Parasitol. 99:141-147.
135. Singh, A. K., B. L. Tekwani, P. Y. Guru, A. K. Rastogi, and V. C. Pandey. 1989. Suppression of the hepatic microsomal cytochrome P-450 dependent mixed function oxidase activities in golden hamster during Leishmania donovani infection. Pharmacol. Res. 21:507-512.
136. Singh, N., R. T. Singh, and S. Sundar. 2003. Novel mechanism of drug resistance in kala azur field isolates. J. Infect. Dis. 188:600-607.
137. Soto. J., B. A. Arana, J. Toledo, N. Rizzo, J. C. Vega, A. Diaz, M. Luz, P. Gutierrez, M. Arboleda, J. D. Berman, K. Junge. J. Engel, and H. Sindermann. 2004. Miltefosine for new world cutaneous leishmaniasis. Clin. Infect. Dis. 38:1266-1272.
138. Soto, J. M., J. T. Toledo, P. Gutierrez, M. Arboleda, R. S. Nicholls, J. R. Padilla, J. D. Herman, C. K, English, and M. Grogl. 2002. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot sludy. Am. J. Trop. Med. Hyg. 66:147-151.
139. Sidhandiran, G., and C, Shaha. 2003. Antimonial-induced increase in intracellular Ca2+ through non-selective cation channels in the host and the parasite is responsible for apoptosis of intracellular Leishmania donovani amastigotes. J. Biol. Chem. 278:25120-25132.
140. Sim, H., S. C. Yan, and W. S. Cheng. 2000. Interaction of antimony tartrate with the tripeptide glutathione implication for its mode of action. Eur. J. Biochem. 267:5450-5457.
141. Sundar, S. 2001. Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health 6:849-854.
142. Sundar, S., T. K. Jha, C. P. Thakur, J. Engel, H. Sindermann, C. Fischer, K. Junge, A. Bryceson, and J. Berman. 2002. Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med. 347:1739-1746.
143. Sundar, S., T. K. Jha, C. P. Thakur, M. Mishra, V. P. Singh. and R. Buffels. 2003. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin, Infect. Dis. 37:800-804.
144. Sundar, S., D. K. More, M. K. Singh, V. P. Singh, S. Sharnia, A. Makharia, P. C. Kumar, and H. W. Murray. 2000. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin. Infect. Dis. 31:1104-1107.
145. Sundar, S.. and H. W. Murray. 2005. Availability of miltefosine for the treatment of kala-azar in India. Bull. W. H. O. 83:394-395.
146. Sundar, S., K. Pai, R. Kumar, K. Pathak-Tripathi, A. A. Gam. M. Ray. and R. T. Kenney. 2001. Resistance to treatment in kala-azar: speciation of isolates from northeast India. Am. J. Trop. Med. Hyg. 65:193-196.
147. Sundar, S., B. B. Thakur, A. K. Tandon, N. R. Agrawal, C. P. Mishra, T. M. Mahapatra, and V. P. Singh. 1994. Clinicoepidemiological study of drug resistance in Indian kala-azar. BMJ 308:307.
148. Teklemariam, S., A. G. Hiwot, D. Frommel, T. L. Miko, G. Ganlov, and A. Bryceson. 1994. Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica. Trans. R. Soc. Trop. Med. Hyg. 88:334-339.
149. Thakur, C. P., J. P. Dedet, S. Narain, and F. Pratlong. 2001. Leishmania species, drug unresponsiveness and visceral leishmaniasis in Bihar, India. Trans. R. Soc. Trop. Med. Hyg. 95:187-189.
150. Thakur, C. P., T. P. Kanyok, A. K. Pandey, G. P. Sinha, C. Messick, and P. Olliaro. 2000. Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study. Trans. R. Soc. Trop. Med. Hyg. 94:432-433.
151. Thakur, C. P., M. Kumar, P. Kumar, B. N. Mishra, and A. K. Pandey. 1988. Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study. BMJ (Clin. Res. Ed.) 296:1557-1561.
152. Thakur, C. P., M. Kumar, and A. K. Pandey. 1991. Evaluation of efficacy of longer durations of therapy of fresh eases of kala-azar with sodium stibogluconate. Indian J. Med. Res. 93:103-110.
153. Thakur, C. P., M. Kumar, S. K. Singh, D. Sharma, U. S. Prasad, R. S. Singh, P. S. Dhawan, and V. Achari. 1984. Comparison of regimens of treatment with sodium stibogluconate in kala-azar. BMJ (Clin. Res. Ed.) 288:895-897.
154. Thakur, C. P., G. P. Sinha, A. K. Pandey, N. Kumar, P. Kumar, S. M. Hassan, S. Narain, and R. K. Roy. 1998. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases. Ann. Trop. Med. Parasitol. 92:561-569.
155. Theiiharides, A. D., H. Chung, und H. Velazquez. 1985. Metabolism of a potential 8-aminoquinoline antileishmanial drug in rat liver microsomes. Biochem. Pharmacol. 34:181-188.
156. Veeken, H., K. Ritmeijer, J. Seaman, and R. Davidson. 2000. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan.
157. Viekers, T. J., and A. H. Fairlamb. 2004. Trypanolhione S-transferase activity in a trypanosomatid ribosomal elongation factor 1B. J. Biol. Chem. 279:27246-27256.
158. Ward, S. A., and P. G. Bray. 2001. Is reversal of chloroquine resistance ready for the clinic? Lancet 357:904.
159. Wasunna, M. K., J. R. RAashid, .J. Mbui, G. Kirigi, D. Kinoti, H. Lodenyo, J. M. Felton, A. J. Sabin, and J. Horton. 2005. A phase II dose-rising study of silamaaquine for the treatment of visceral leishmaniasis in Kenya. Am. J. Trop. Med. Hyg. 73:871-876.
160. White, N. J., and W. Pongtavornpinyo. 2002. The de novo selection of drug-resistant malaria parasites. Proc. R. Soc. Lond. B 270:545-554.
161. Wyllie, S., M. L. Cunningham. and A. H. Fairlamb. 2004. Dual action of antimonial drugs on thiol rcdox metabolism in the human pathogen Leishmania donovavi J. Biol. Chem. 279:39925-39932.
162. Van, S., F. Li, K. Ding, and U. Sun. 2003. Reduction of pentavalent antimony bhy trypanothione and formation of a binary and ternary complex of antimony(III) and trypanothione. J. Biol. Inorg. Chem. 8:689-697.
163. Van, S. C., I. L. K. Wang, L. M. C. Chow, and H. Z. Sun. 2003. Rapid reduction of pentavalent antimony by trypanothione: potential relevance to antimonial activation. Chem. Commun. 2:266-287.
164. Yardley, V., S. L. Croft, S. De Donker, J. C. Dujardin, K. Siddhartha, C. Miranda, A. Llanos-Cuentas, and F. Chappuis. 2005. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltetosine. Am. J. Trop. Med. Hyg. 73:272-275.
165. Yeates, C. 2002. Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute). Curr. Opin. Investig. Drugs 3:1446-1452.
166. Young, L. Y., C. M. Hull, and J. Heitman. 2003. Disruption of ergosterol biosynthesis confers resistance to amphoteriein B in Candida lusitaniae. Antimicrob. Agents Chemother. 47:2717-2724.
167. Zhou, Y., N. Messier, M. Ouellette, B. P. Rosen, and R. Mukhopadhyay. 2004. Leishmania major LmACR2 is a pentavalent antimony reduclase that confers sensitivity to the drug Pentostam. J. Biol. Chem. 279:37445-37451.